Table of Contents

1. LAMN Treatment After Surgery
2. Immunotherapy in Appendix Cancer
3. Goblet Cell Appendix Cancer
4. Appendix Cancer Risk and Tumor Rupture
5. Final Thoughts

---

Appendix cancer research is evolving, and several new studies that showed up in my inbox today are helping clarify how different types of the disease behave and respond to treatment.

Recent findings focus on four important areas:

• Treatment decisions after LAMN removal
• The role of the immune system in immunotherapy
• Why goblet cell appendix cancer may be a distinct disease
• What increases the risk of pseudomyxoma peritonei (PMP)

These studies are early, but they reflect a broader shift toward more personalized care in appendix cancer.

LAMN Treatment After Surgery: Should HIPEC Be Considered?

Study link: https://doi.org/10.21203/rs.3.rs-3874943/v1
Status: Preprint, not peer reviewed

Institution: Aerospace Center Hospital, China

Low-grade appendiceal mucinous neoplasm, or LAMN, is often treated with surgical removal. The question many patients face is whether additional treatment like HIPEC is necessary after surgery.

In this study of 159 patients, researchers compared outcomes between patients who underwent prophylactic cytoreductive surgery with HIPEC and those who were monitored with observation alone.

The study reported:

• Fewer recurrences in the HIPEC group
• Longer recurrence-free survival, 48 months versus 36 months

The authors suggest that some higher-risk patients may benefit from additional surgical procedures, including removal of the greater omentum and, in women, the ovaries and fallopian tubes.

What patients should understand

This study is based on a small number of recurrences and has not been peer reviewed. It does not establish a standard treatment approach.

For patients with LAMN, the decision to pursue HIPEC after surgery depends on individual risk factors, pathology findings, and consultation with experienced specialists.

Immunotherapy in Appendix Cancer

Study link: https://doi.org/10.1158/1538-7445.AM2026-3953
Status: AACR 2026 conference abstract

Institutions: MD Anderson Cancer Center and collaborators

Immunotherapy has shown limited and inconsistent results in appendix cancer. New research is beginning to explore whether the tumor microenvironment plays a role in treatment response.

In this study, researchers analyzed tumor samples from eight patients using spatial proteomics to examine immune cell patterns.

Patients were grouped based on whether they were alive or deceased at follow up.

Key findings include:

• Immune cell clusters were present in most tumors
• Patients alive at follow up showed trends toward more active immune cell structures
• Patients who were deceased had higher levels of immune suppressing cells

Why this matters

These findings suggest that differences in the immune environment may influence how appendix cancer responds to immunotherapy.

Important context

This is early-stage research with a very small sample size. It does not yet provide a way to predict treatment response in clinical practice.

Goblet Cell Appendix Cancer

Study link: https://doi.org/10.1158/1538-7445.AM2026-4125
Status: AACR 2026 conference abstract

Institutions: MD Anderson Cancer Center, Natera Inc., and collaborators

Goblet cell adenocarcinoma of the appendix is a rare subtype that accounts for about 15 percent of cases. It has often been grouped with other appendiceal cancers, but new research suggests it should be treated separately.

This study analyzed more than 1,200 tumors and found that goblet cell tumors have a different molecular profile compared to other appendiceal cancers.

Key findings include:

• Different mutation patterns compared to mucinous tumors
• Activation of distinct biological pathways
• Worse overall survival, with a significantly higher risk of death

What this means for patients

Goblet cell appendix cancer may require different treatment strategies and should not be assumed to behave like other types of appendix cancer.

Important context

This research is based on a conference abstract and is still evolving. More studies are needed before this changes treatment guidelines.

Appendix Cancer Risk and Tumor Rupture

Full abstract: https://assets.cureus.com/uploads/original_article/pdf/459278/20260308-144806-icrvy2.pdf
Status: Retrospective single-center study, small sample size – Institution: Hospital Médica Sur, Mexico City

One of the most important questions in appendix cancer is what actually increases the risk of developing pseudomyxoma peritonei, or PMP.

This study looked at 30 patients with appendiceal mucinous neoplasms, including both low-grade and high-grade tumors, and compared those who developed PMP with those who did not.

What they found

Appendiceal perforation was the only factor significantly associated with the development of PMP.

• Patients with rupture had a much higher likelihood of developing disease spread
• Absence of rupture was associated with significantly lower risk

Other factors showed trends but were not statistically significant:

• Higher-grade tumors such as HAMN
• Tumor markers like CEA, CA 125, and CA 19-9

Why this matters

When the appendix ruptures, mucin and tumor cells can spill into the abdominal cavity. This is how PMP develops.

This means that even low-grade tumors like LAMN can behave more aggressively if rupture occurs.

What patients should understand

This study reinforces a key concept already recognized in appendix cancer care:

• Surgical technique matters
• Avoiding rupture during removal is critical
• If rupture has occurred, follow-up may need to be more aggressive

Important context

This study includes only 30 patients and should be interpreted as exploratory. Larger studies are needed to confirm these findings.

What These Studies Mean for Appendix Cancer Patients

These findings highlight an important shift in how appendix cancer is being understood.

• Not all LAMN cases carry the same risk
• The immune system may influence treatment response
• Tumor subtype, especially goblet cell, matters
• Surgical factors like rupture can significantly impact outcomes

Appendix cancer is not a single disease, and treatment decisions are becoming more individualized.

Final Thoughts

While these studies are early, they represent meaningful progress in a rare cancer that has historically received limited attention.

For patients and caregivers, staying informed and working with experienced specialists remains critical as research continues to evolve. As always, share this information with your medical team.